Alligator Bioscience AB reports financial results for Q2 2025 and provides a business update
GMP manufacturing completed, paediatric waiver granted, positive outcome from FDA and EMA interactions; advancing mitazalimab toward Phase 3 ...
Alligator Bioscience publishes Annual Report for 2024
Lund, Sweden, 27 March 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2024, as well ...
Alligator Bioscience AB reports financial results for H1 2024 and Q2 2024 and provides a business update
Substantial overall survival benefit and unprecedented Duration of Response reported in 18-month analysis from mitazalimab OPTIMIZE-1 Phase ...
Alligator Bioscience publishes Annual Report for 2023
Lund, Sweden, March 21, 2024 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2023, as ...
Alligator Bioscience AB reports financial results for H1 2023 and Q2 2023 and provides a business update
Positive second interim analysis from OPTIMIZE-1 Phase 2 study shows increase in ORR* and favorable DoR** suggesting durable benefits of mit ...
Alligator Bioscience publishes Annual Report for 2022
Lund, Sweden, March 24, 2023 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2022 has been publi ...
Alligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business update
· Mitazalimab OPTIMIZE-1 interim data and ATOR-1017 Phase 1 on track to readout in H2 2022 · Decision to leverage OPTIMIZE-1 interim data be ...
Alligator Bioscience publishes Annual Report for 2021
Lund, Sweden, March 22, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Annual Report for 2021 has been publi ...
Alligator Bioscience AB: Year End report January–December 2021
OPTIMIZE-1 Phase II – On Track and Moving Forward “During the fourth quarter 2021, Alligator reached several key milestones in our pre-clini ...